

## Revolving Fund: A Pillar in a Successful Regional Immunization Program for the Americas

17<sup>th</sup> Meeting of DCVMN Buenos Aires, October 24 – 27, 2016

www.paho.org/immunization www.paho.org/revolvingfund





# Content

- Overview of PAHO's Regional Immunization Program
- Revolving Fund (RF) as a Pillar of Program's Technical Cooperation to Member States

## Our Challenges:

- Availability of some vaccines
- High costs of other vaccines
- Our Vision





## PAHO Member States and its Revolving Fund for Vaccines

- 1977 CD25.R27 "Establishment of the Expanded Program on Immunization (EPI) and the PAHO Revolving Fund"
- 2013 CD52R5 "Principles of the PAHO Revolving Fund for Vaccine Procurement"
- 2013 CD52/15 "Review of the Charge Assessed on the Procurement of Public Health Supplies for Member States"
- 2014 CD53/23 Report "PAHO Revolving for vaccine procurement: Challenges and Opportunities"








## Milestones in the 39 years of the EPI in the Americas


4077				$\rightarrow$	
1977 PAHO's Directing Council establishes the EPI	1979	Creation of the Revolving Fund	2016	2017	
	1980	Creation of international evaluation methodo	logy for the EPI		
	1983	"Days of Tranquility"		<image/> <image/> <text><text><text><text></text></text></text></text>	
	1985	Creation of the EPI Technical Advisory Group			
	1985	Creation of the Interagency Cooperation Comm	nittee		
	1991	Last indigenous case of polio in Peru			
	1994	Declaration of the goal to eliminate measles			
	1994	1 <sup>st</sup> Region certified free of polio			
	2003	1 <sup>st</sup> Vaccination Week in the Americas			
	2006	Launch of the Pro-Vac initiative			
	2010	Directing Council resolution on strengthening t	the EPI (RIVS)		
	2012	1st World Immunization Week			
	2013	Directing Council resolution on the principles	of the RF		
	2015	1st Region free of rubella			
	2015	Directing Council resolution on the Regional Im	nm Action Plan		
	2016	OPV Switch			
	2016	1st Region free of measles			

## **Considerations for New Vaccine Policymaking**




Source: Andrus, JK., Toscano, CM., Lewis, M., Oliveira, L., et al. 2007, "A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac Initiative", *Public Health Reports*, 122(6): 811-816.

### **Introduction of New Vaccines in the Americas**



5 Fuente: Country Reports to PAHO-WHO-UNICEF (JRF), 2016

## PAHO's Sustainability Model for Immunizations



## **Key Enablers for RF Success**

High Level of Commitment from Member Countries "Solidarity", WHA & DC Resolutions

Quality Vaccines Manufacturers

## The PAHO Revolving Fund

"Facilitating Access"













#### "Every year more vaccines are delivered by DCVMN manufacturers through PAHO Revolving Fund"




#### Procured Value (US\$ Million)











#### Summary of Uptake of New Vaccines and Immunization Coverage (DPT3) in the Americas

"Percent Districts with >95% coverage (DTP3) reduced in last 4 years"









## **Addressing Supply of EPI Vaccines**

- Supply meets or exceeds demand for most vaccines, however the market continues to evolve
- Currently some critical shortages of prequalified products (YF, IPV)
- RF has increased vaccine eligibility opportunities (8 NRAs of reference) Attend PAHO's Q&A session for more details
- How may PAHO help DCVMN members address:
  - Expansion of supply of strategic vaccines?
  - Leverage regional production capacities?
  - Decision making on product design/presentation preference?





### **RF Assessment: Transforming our Business Model**

#### **Current State**

National immunization programs are increasingly challenging PAHO to strengthen the Revolving Fund.

#### **Envisioned State**

Review Revolving Fund's operating model and complete a detailed assessment to identify broad-based improvement opportunities

Increasing complexities of the global context in which the RF operates, e.g. vaccine markets, actors and technology

Changes in business environments (supply base) as well as technology and infrastructure require a revitalization of vaccine procurement supply chain

RF wants to provide more efficient solutions and quality products on a timely and cost-effective basis to the Member States Alternative business models will be reviewed and a consensus derived with stakeholders (Member States) from those proposed and evaluated

Create a blueprint of a transformed RF business model framework

The forces impacting RF business model - demand, supply and logistics – will be evaluated and a roadmap proposed for RF transformation





## Thank you!



www.paho.org/revolvingfund